Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
781-800 of 2,251 trials

Alpha-1 Antitrypsin Deficiency Emphysema: SAR447537 Study

We are studying the long-term safety of SAR447537 in adults with alpha-1 antitrypsin deficiency emphysema. The trial will also evaluate its effects on lung health and how the body processes the treatment.

Alpha-1 Antitrypsin Deficiency (AATD) Emphysema>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

INBRX-109 for Advanced Solid Tumors, Including Sarcomas

We are studying a new treatment, INBRX-109, in combination with chemotherapy for adults and adolescents with advanced solid tumors like Ewing sarcoma and colorectal cancer. The goal is to assess its safety and how well it works compared to current treatments.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Intrathecal Baclofen for Spinal Cord Injury: Safety Study

We are investigating whether intrathecal baclofen is safe for spinal cord injury patients, particularly regarding lung function and sleep disorders. The study also looks at its potential to reduce muscle stiffness and improve daily activities.

Spinal Cord Injury>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyPulmonology

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Crohn's Disease: Vedolizumab vs. Adalimumab Dose Increase

We are studying whether Vedolizumab is more effective than increasing the dose of Adalimumab for Crohn's disease patients who are not responding well to their current treatment. This trial will help us understand which strategy leads to better remission and fewer side effects.

Crohn's Disease3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Uveal Melanoma: New Liver Treatment with Ipilimumab and Nivolumab

We are testing a new liver treatment combined with two immunotherapy drugs for patients with uveal melanoma that has spread to the liver. This study aims to see if the new approach improves survival without disease progression compared to standard treatment.

Uveal Melanoma with Liver Metastases3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHepatologyOncology

Fragile X Syndrome: Long-Term Study of ZYN002 Gel

We are examining the long-term safety and tolerability of a gel medication for children and young adults with Fragile X Syndrome. This study includes participants who have previously used the medication and are continuing to see if it helps manage their symptoms.

Fragile X Syndrome≤3 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurologyPediatrics

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

Chronic Inflammatory and Fibrotic Diseases: 68Gallium-FAPI PET/CT Imaging Study

We are exploring how a new imaging method can help assess chronic inflammatory and fibrotic diseases. This study aims to understand the relationship between imaging results and disease severity, quality of life, and other health indicators.

Inflammatory Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational Medicines

Meningococcal B Vaccine for Adults with Asplenia

We are studying the safety and immune response of the BEXSERO® vaccine in adults without a spleen. This trial compares their response to healthy individuals to ensure effective protection against meningococcal disease.

Splenectomy6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Hepatocellular Carcinoma: Atezolizumab-Bevacizumab with Bacterial Supplements

We are studying whether adding bacterial supplements to a combination of atezolizumab and bevacizumab helps patients with hepatocellular carcinoma who have not responded to first-line treatment. The trial also looks at the safety of this new approach.

Non-resectable Hepatocellular Carcinoma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib and Defactinib Study

We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.

Recurrent Low-Grade Serous Ovarian Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Zanidatamab for Advanced HER2-Positive Biliary Tract Cancer

We are studying whether zanidatamab combined with standard chemotherapy helps patients with advanced HER2-positive biliary tract cancer more than standard chemotherapy alone. This trial aims to evaluate its effectiveness and safety.

Biliary Tract CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Inflammatory Bowel Disease: Intravenous Lidocaine Study

We are investigating whether intravenous lidocaine can reduce abdominal pain in patients with chronic inflammatory bowel disease. Additionally, we will study how this treatment affects brain activity compared to healthy volunteers.

Inflammatory Bowel Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

MDMA-Assisted Therapy for Treatment-Resistant PTSD

We are studying whether MDMA-assisted therapy can improve symptoms of PTSD in individuals who have not responded to other treatments. This trial also looks at how well this therapy works in a hospital setting.

Posttraumatic Stress Disorder6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

HER3-Targeted Imaging with Patritumab Deruxtecan

We are studying the best dose of a new imaging agent for patients with tumors that express HER3. This research aims to improve how we visualize and understand tumor response to treatment.

EGFR Mutation Positive Advanced Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Severe Systemic Lupus Erythematosus: Obecabtagene Autoleucel Study

We are studying a new treatment for patients with severe, hard-to-treat systemic lupus erythematosus. The trial aims to evaluate its safety, tolerability, and early signs of effectiveness.

Severe Systemic Lupus ErythematosusSafety phase (I)No PlaceboInvestigational MedicinesInternal MedicineRheumatology